News

Kris Hans shares how Biosenta is tackling the antimicrobial health crisis at the source, and why this work matters now more than ever.

Biosenta Inc. Achieves Major Breakthroughs in Bench Scale Production and Innovative Input Viability.

Biosenta announces significant advancements at its state-of-the-art bench scale production facility.

Biosenta has been making the innovative strides in the realm of antimicrobial biotechnology.

Biosenta Inc. announces licensing agreement

Biosenta granted to Lightweight Concrete Solutions a license to use Biosenta’s Tri-Filler® technology and get fee of C$200,000 and royalties

Biosenta announces technological and operational advancements with successful construction and operation of a bench scale production plant.

Discover Biosenta's exciting engagement with Oak Hill Financial, offering insight into their business and capital markets advisory services.

Discover how Biosenta successfully closed a private placement financing of $500,000 for its future growth and development.

Biosenta announces a pivotal discovery revealed that Tri-Filler™ effectively sterilizes a wide range of microorganisms.

Biosenta will test Tri-Filler™ in plastics at AMPAK Inc. facilities with an eye to commercialization.

Biosenta will test Tri-Filler™ in plastics at AMPAK Inc. facilities with an eye to commercialization.

Biosenta Inc. announces further advances in research and development of Tri-Filler™

Biosenta Inc. announces further advances in research and development of the Tri-Filler™ particle.

Chelsey Reschke is one of 47 Canadians attending the G20 Young Entrepreneurs’ Alliance summit in Hamburg from Oct. 27 to 28.

Biosenta Inc. has signed an MOU with Voran Group Ventures Ltd. for the commercialization of Biosenta’s Tri-Filler® antimicrobial products.

How to mix the right ingredients for an environmentally friendly disinfectant

University of Calgary very encouraging anti-bacterial Biosenta particles for construction industry

Biosenta announces that it has granted to certain directors, officers, employees and consultants of the Company 350,000 stock options.

Biosenta will enter into a series of prime plus 5% unsecured promissory notes in consideration for cash investments in the amount of $85,000